替尔泊肽在中国超重/肥胖成人中的疗效和安全性:一项随机对照试验  

Efficacy and safety of tirzepatide for weight reduction in Chinese adults with overweight/obesity:A randomized clinical trial

作　　者：赵琳 成志锋[2] 鲁一兵[3] 刘铭[4] 陈宏[5] 张敏 王睿 袁媛 李小英 Zhao Lin;Cheng Zhifeng;Lu Yibing;Liu Ming;Chen Hong;Zhang Min;Wang Rui;Yuan Yuan;Li Xiaoying(Department of Endocrinology and Metabolism,Zhongshan Hospital,Fudan University,Shanghai 200032,China;Department of Endocrinology,Fourth Affiliated Hospital of Harbin Medical University,Harbin 150023,China;Department of Endocrinology,The Second Affiliated Hospital of Nanjing Medical University,Nanjing 210011,China;Department of Endocrinology and Metabolism,Tianjin Medical University General Hospital,Tianjin 300070,China;Department of Endocrinology,Zhujiang Hospital,Southern Medical University,Guangzhou 510260,China;Department of Endocrinology and Metabolism,Qingpu Branch of Zhongshan Hospital,Fudan University,Shanghai 201799,China;Eli Lilly and Company,Shanghai 200003,China)

机构地区：[1]复旦大学附属中山医院内分泌科,上海200032 [2]哈尔滨医科大学附属第四医院内分泌科,哈尔滨150023 [3]南京医科大学第二附属医院内分泌科,南京210011 [4]天津医科大学总医院内分泌代谢科,天津300070 [5]南方医科大学珠江医院内分泌代谢科,广州510260 [6]复旦大学附属中山医院青浦分院内分泌科,上海201799 [7]礼来公司,上海200003

出　　处：《中华内分泌代谢杂志》2024年第8期637-640,共4页Chinese Journal of Endocrinology and Metabolism

摘　　要：本文介绍2024年5月31日在《美国医学会杂志》发表的论文"Tirzepatide for weight reduction in Chinese adults with obesity:The SURMOUNT-CN randomized clinical trial"的设计、主要结果及其意义。该研究为替尔泊肽治疗肥胖的首项中国证据,为肥胖及其合并症的防治提供了强有力的治疗手段。This article introduces a recent paper published in JAMA titled"Tirzepatide for weight reduction in Chinese adults with obesity:The SURMOUNT-CN randomised clinical trial".The paper details the design,results,and implications of a randomized controlled clinical study of the efficacy and safety of tirzepatide in overweight/obese adults in China(SURMOUNT-CN).This study represents the first Chinese evidence supporting tirzepatide for the treatment of obesity,offering a potent therapeutic option for the prevention and treatment of obesity and weight-related comorbidity.

关 键 词：替尔泊肽 胰升糖素样肽-1/葡萄糖依赖性促胰岛素释放多肽受体激动剂 肥胖症 

分 类 号：R589.2[医药卫生—内分泌]